Despite End-Market Concerns, Genomic Tools Vendors Keep up R&D Pace | GenomeWeb

By Tony Fong

NEW YORK (GenomeWeb News) – Despite an uncertain economy and softness in key end markets, genomic tools and molecular diagnostics firms continued to invest in new technologies as R&D spending through the first half of 2011 rose 13 percent year over year among the firms tracked in the GenomeWeb Daily News Index.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: nanopore sequencing workflow to detect antibiotic resistance in gut microbes, TSSPlant tool, and more.

Because gene-edited organisms can cross borders, Gizmodo wonders whether there should be an international body to govern their use.

HHS Secretary nominee Tom Price is to go in front of the Senate Committee on Health, Education, Labor and Pensions today, NPR's Morning Edition reports.

Prior to being closed, Theranos' Arizona lab failed an inspection by regulators, according to the Wall Street Journal.